Angiosarcoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Angiosarcoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ Wed, 29 Apr 2026 14:59:55 +0000 https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ This clinical trial studies a treatment for soft tissue sarcoma, a type of cancer that develops in soft tissues like muscles and fat. The study focuses on patients whose cancer has spread to other parts of the body (metastatic) or who did not respond well to previous treatments. The trial compares two treatment approaches: one using only trabectedin (a chemotherapy medication) and another combining trabectedin with tTF-NGR (an experimental drug).

The study aims to determine if adding tTF-NGR to standard trabectedin treatment helps keep the cancer under control for a longer time. Both medications are given through an intravenous infusion directly into the bloodstream. The experimental drug tTF-NGR is designed to concentrate the chemotherapy medication inside the tumor.

During the study, participants receive treatment for up to 360 days. Some patients will receive only trabectedin, while others will receive both trabectedin and tTF-NGR. Regular medical examinations and imaging tests will be performed to monitor how the cancer responds to the treatment. The study focuses on patients whose tumors show a specific characteristic called CD13 positivity, which is determined through laboratory testing.

]]> Study on Propranolol and Pembrolizumab for Patients with Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma https://clinicaltrials.eu/trial/study-on-propranolol-and-pembrolizumab-for-patients-with-advanced-angiosarcoma-and-undifferentiated-pleomorphic-sarcoma/ Wed, 29 Apr 2026 14:29:06 +0000 https://clinicaltrials.eu/trial/study-on-propranolol-and-pembrolizumab-for-patients-with-advanced-angiosarcoma-and-undifferentiated-pleomorphic-sarcoma/ This clinical trial is focused on studying two types of cancer: Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma. These are rare and aggressive forms of cancer that can occur in various parts of the body. The study will explore the effects of a combination treatment using two medications: Propranolol Hydrochloride and Pembrolizumab. Propranolol Hydrochloride is a type of medication known as a beta-blocker, which is commonly used to treat heart conditions but is being investigated here for its potential effects on cancer. Pembrolizumab, also known by its brand name Keytruda, is an immunotherapy drug that helps the immune system fight cancer cells.

The purpose of this study is to evaluate how well this combination treatment works in controlling the growth of these cancers over a period of three months. Participants in the study will receive both medications, with Propranolol Hydrochloride taken orally in the form of tablets and Pembrolizumab administered through an intravenous infusion, which means it is given directly into a vein. The study will monitor the participants’ health and the progression of their cancer during this time.

Throughout the study, participants will have regular visits to the clinic for treatment and monitoring. This will include various tests and assessments to track the cancer’s response to the treatment. The study aims to provide valuable information on whether this combination of medications can help improve outcomes for patients with these challenging types of cancer.

]]>